Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 204S204 trades$51.20M
Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
TSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
MTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
MSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
FFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
ULCCFrontier Group Holdings, Inc.Nov 5 – Nov 117 insiders$1.31M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Bruno Marc ACOO, U.S. Food & Facilities |  ARMKAramarkOption exercise | M | — 74.7K sh | Aug 14, 2026 |
| 9 | Amoo-Gottfried Kofi OwusuDirector |  HIMSHims & Hers Health, Inc.Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Baetz Cary DEVP and CFO |  INRINFINITY NATURAL RESOURCES, INC.Grant or award | A | — 31.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Derakhshan BehradChief Business Officer |  EWTXEdgewise Therapeutics, Inc.Grant or award | A | — 100.0K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Mottola FrankSVP, Chief Tech. Ops. Officer | SUPNSUPERNUS PHARMACEUTICALS, INC. Option exercise | M | — 1,650 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Rubin JonathanSVP, Chief Medical Officer | SUPNSUPERNUS PHARMACEUTICALS, INC. Tax withholding | F | $17K 363 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Cosgrove Delos M.Director | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Russo Joseph J.EVP&Pres-Global Networks&Tech |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,104 80 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Villanueva Rodriguez AlfonsoEVP and Group CEO-VZ Consumer | VZVERIZON COMMUNICATIONS INC Grant or award | A | $1,738 126 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Bradshaw James HendersonDirector |  RLIRLI CORPGrant or award | A | — 2,153 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Trebbi BarbaraDirector |  BLCOBausch & Lomb CorpGrant or award | A | — 11.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Baetz Cary DEVP and CFO | INRINFINITY NATURAL RESOURCES, INC. Grant or award | A | — 31.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Paul Laurence EDirector | BLCOBausch & Lomb Corp Grant or award | A | — 11.8K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Payne Christopher DDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 545 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Elshenawy MohamedCTO | HIMSHims & Hers Health, Inc. Grant or award | A | — 1.20M sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Malady KyleEVP and Group CEO-VZ Business | VZVERIZON COMMUNICATIONS INC Grant or award | A | $1,738 126 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Wells David BDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 778 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Nofi MichaelChief Financial Officer | EWTXEdgewise Therapeutics, Inc. Grant or award | A | — 24.4K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Kalish MatthewDirector |  DKNGDraftKings Inc.Option exercise | M | — 383.5K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Schultz KareDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Wells David BDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Rubin JonathanSVP, Chief Medical Officer | SUPNSUPERNUS PHARMACEUTICALS, INC. Option exercise | M | — 750 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 9 | Bruno Marc ACOO, U.S. Food & Facilities | ARMKAramark Option exercise | M | — 57.1K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 9 | Schmitt Daniel MDirector, President, CEO and Director |  ACTUACTUATE THERAPEUTICS, INC.Option exercise | M | — 272.1K sh | Aug 14, 2026 traded Aug 14, 2026 |
| 9 | Manuel AnjaDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 8 | Kurtz GeorgeDirector, PRESIDENT AND CEO | CRWDCrowdStrike Holdings, Inc. Open-market sale · 10b5-1 plan | SELL | $18K 80 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 8 | Kurtz GeorgeDirector, PRESIDENT AND CEO | CRWDCrowdStrike Holdings, Inc. Open-market sale · 10b5-1 plan | SELL | $26K 120 sh | Aug 14, 2026 traded Aug 13, 2026 |
| 8 | Watts Ryan J.Director, President and CEO |  DNLIDenali Therapeutics Inc.Gift | G | — 32.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 7 | Grawunder UlfDirector |  ADAGAdagene Inc.Grant or award · 10b5-1 plan | A | — 20.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 5 | Haas JasonDirector | LGNDLIGAND PHARMACEUTICALS INC Option exercise | M | — 6,138 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Russell Alan JDirector, Chief Scientific Officer | EWTXEdgewise Therapeutics, Inc. Grant or award | A | — 32.5K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Fukushima RyanCEO, Data |  TEMTempus AI, Inc.Gift | G | — 62.2K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Carroll Patrick HarrisonChief Medical Officer | HIMSHims & Hers Health, Inc. Grant or award | A | — 260 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Perez Garcia Andrea GDirector | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Autor Deborah M.Director, Chief Policy Officer | HIMSHims & Hers Health, Inc. Grant or award | A | — 8,223 sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Russell Alan JDirector, Chief Scientific Officer | EWTXEdgewise Therapeutics, Inc. Grant or award | A | — 65.0K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 5 | Akerib AvidanVP, Associative Computing |  GSITGSI TECHNOLOGY INCGrant or award | A | — 40.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 4 | Clark KyleDirector, SEE REMARKS |  BETABETA Technologies, Inc.Open-market sale · 10b5-1 plan | SELL | $763K 30.0K sh | Aug 14, 2026 traded Aug 13, 2026 |
| 4 | Clark KyleDirector, SEE REMARKS | BETABETA Technologies, Inc. Open-market sale · 10b5-1 plan | SELL | $352K 15.0K sh | Aug 14, 2026 traded Aug 12, 2026 |
| 2 | Espinoza OctavioChief Financial Officer | LGNDLIGAND PHARMACEUTICALS INC Option exercise · 10b5-1 plan | M | $410K 7,171 sh | Aug 14, 2026 traded Aug 12, 2026 |